1 Modelling valuations for the EQ-5D health states: an alternative model using differences in valuations Jennifer Roberts and Paul Dolan Sheffield Health.

Slides:

Advertisements

Similar presentations

Policy Changes, Caregiving and Support: Implications for Aging Lesbians Korijna Valenti, M.A, M.S. Gerontology Anne D. Katz, PhD, LCSW Background Sample.

Advertisements

Quality of life and subjective well-being Paul Dolan Director, Centre for Well Being in Public Policy University of Sheffield, Sheffield, UK [But soon.

1 Could there be a single European EQ tariff? Jan J.V. Busschbach, Ph.D. Former address: –iMTA, Erasmus university Present address: –Medical Psychology.

Using Household Surveys to Study the Economic and Social Implications of Migration: A Methodological Evaluation* Regional Training Workshop on International.

Big Q and Little Q revisited Christopher McCabe PhD Capital Health Endowed Research Chair in Emergency Medicine Research.

1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren

Two ways to skin a cat: a comparison of two variants of standard gamble John Brazier and Paul Dolan Prepared for the CHEBS workshop on Elicitation, 9 October.

Understanding Factors Affecting Consumer Purchase Decisions for Functional Foods By Ratapol Teratanavat Dr. Neal H. Hooker Presented at the IFT Meeting,

Valuing Health Daniel M. Hausman University of Wisconsin-Madison October 19, 2009.

Valuing the SF-6D: a nonparametric approach using individual level preference data Part 1): The SF-6D and its valuation Samer A Kharroubi, Tony O’Hagan,

Modelling Cardinal Utilities from Ordinal Utility data: An exploratory analysis Peter Gilks, Chris McCabe, John Brazier, Aki Tsuchiya, Josh Solomon.

Estimating utilities from individual preference data Some introductory remarks by Tony O’Hagan.

Utilising rank and DCE data to value health status on the ‘QALY’ scale using conventional and Bayesian methods John Brazier and Theresa Cain with Aki Tsuchiya.

25 Sept 07 FF8 - Discrete Choice Data Introduction Tony O’Hagan.

1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.

1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.

Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.

MAPPING THE DIABETES HEALTH PROFILE (DHP-18) ONTO THE EQ-5D AND SF-6D GENERIC PREFERENCE BASED MEASURES OF HEALTH Brendan Mulhern 1, Keith Meadows 2, Donna.

1 EQ-5D, HUI and SF-36 Of the shelf instruments…..

Overview of the EQ-5D Purpose and origins of the descriptive system.

Statistical Techniques I EXST7005 Factorial Treatments & Interactions.

1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.

Is healthcare any good for patients? Measuring health outcomes using EQ-5D Professor Paul Kind Principal Investigator Outcomes Research Group Centre for.

Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.

How can societal concerns for fairness be integrated in economic evaluations of health programs? Erik Nord, PhD, Senior Researcher, Norwegian Institute.

Chapter Eight The Concept of Measurement and Attitude Scales

Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.

New and ongoing areas of research In the EuroQol Group.

1 Patient values or values from the general public.

1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.

Key issues from yesterday and for panel Lorraine Dearden.

Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)

Evidence and Information for Policy Health as a multi-dimensional construct and cross-population comparability Colin Mathers (WHO) on behalf of Taskforce.

1 EQ-5D, HUI and SF-36 Of the shelf instruments…..

The art of SNAP decisions and the science of well-being as they apply to health Paul Dolan Imperial College Business School.

1 Effects of Medicaid Policy on Long-Term Care Decisions and Medical Services Utilization among the Low-Income Elderly Song Gao SUNY-Stony Brook.

Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.

1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.

Using a Discrete Choice Experiment to Value the EQ-5D-5L in Canada Nick Bansback Assistant Professor School of Population and Public Health, University.

1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren

Health Related Quality of Life: Prevalence and Its Associate on the Intention to Leave Nursing Career. Nittaya Phosrikham.

“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.

Chapter Two Methods in the Study of Personality. Gathering Information About Personality Informal Sources of Information: Observations of Self—Introspection,

(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.

Effect of framing of death on health state values obtained from DCEs Dr. Esther W. de Bekker-Grob by Jonker, de.

Welfare Working Group Forum, 10 June 2010 The origins of the benefit system An iconoclastic view 1 Forum, 10 June 2010 The origins of the benefit system.

1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.

Feng Xie Department of Clinical Epidemiology and Biostatistics McMaster University.

School of Allied Health Professions & School of Medicine, Health Policy & Practice LAMP A pragmatic unblinded randomised controlled trial and economic.

LSE Summit Rethinking regulation and value assessment of medical technologies: challenges and opportunities Valentina Prevolnik Rupel, PhD Institute for.

Quality of Life Lost due to Road Crashes Patricia Cubí-Mollá University of Alicante XXXIII SIMPOSIO DE ANÁLISIS ECONÓMICO ZARAGOZA 2008 Job Market Paper.

Canadian TTO Valuations of the EQ-5D-5L: East versus West Differences

Professor Nancy J. Devlin Office of Health Economics Royal Statistical Society June 18 th 2015 Measuring and ‘valuing’ patient reported health.

Globalisation…. What is globalisation? Definition of globalisation ‘The ability to produce any goods (or service) anywhere in the world, using raw.

Is there a fertility convergence across the Member States of the EU?

Quality of Life in a City

Effect of framing of death on health state values obtained from DCEs

Quality Systems Management

Quality Systems Management

Quality Systems Management

Quality Systems Management

Quality Systems Management

Quality Systems Management

Katie Sherron Economics

Is healthcare any good for patients

6/18/ Pair 1 Pair 2 3 levels of LC severity Pair 3 Pair 4

Conclusive Research Descriptive Studies

Changes in Women’s Empowerment in Turkey

Measuring outcomes Emma Frew October 2012.

Suffering from Depression

Presentation transcript:

1 Modelling valuations for the EQ-5D health states: an alternative model using differences in valuations Jennifer Roberts and Paul Dolan Sheffield Health Economics Group

2 The EQ-5D Mobility Self Care Usual Activities Pain/Discomfort Anxiety/Depression – 3 levels defining problems on each dimension (none, some, a lot).

3 Motivation the original EQ-5D study preference based single index – 42 states (from 243) valued by TTO – i = 2997, j = 12, n = 35,964 – ‘tariff’ produced (Dolan 1997) – predicts mean health state values quite well despite – enormous variation across individual valuations of states

4 Descriptive Statistics for TTO Values StateMeanS.D

5 Differences in Health States State AState BNDIF(A-B)SD% Neg99%CI

6 Agreement with pair wise ranking of states

7 The data for the new tariff model all respondents valued plus 11 others – 2 very mild (n  1200) – 3 each from mild, moderate and severe (n ~ 750) consider each respondents value of each state as the difference from their value for – i = 2997, j = 11, n = 32,967 – random effects model used

8 Tariff Results C DIFMOB10.320DIFPAIN DIFMOB20.391DIFPAIN DIFSC10.179DIFMOOD DIFSC20.280DIFMOOD DIFUA10.084ANY DIFUA R 2 within0.554No > |0.05)8 MAE0.03No > |0.10|1

9 Comparing the old and new tariffs

10 Conclusion Lack of consensus on ordering of states has implications for policy decisions … Two models are similar in structure and findings New model has better predictive ability Some important differences arise – difference in health change given by the two tariffs could be as much as Which (if any) is the right model?